Cannabinoids are chemical compounds naturally occurring in the cannabis plant (cannabis sativa). Cannabidiol (CBD) is one of these chemicals and studies have shown it has anti-inflammatory effects when induced on animal cells. People have smoked the marijuana plant for thousands of years and it has said have an anti-inflammatory role in the body. Tetrahydrocannabinol (THC) is another one of these chemicals and it is said it has psychoactive effects.
Major cannabinoid receptors (CB1 and CB2) are found in the endocannabinoid system and allow exogenous and endogenous cannabinoids to thrive in the body. Cannabinoids for these receptors include the endocannabinoid system, that is produced in the body by animals, the plant cannabinoids in cannabis and some other plants, and synthetic cannabinoids. Keep reading to see if cannabinoids could be made into novel medications to treat disorders arising from drug addiction.
Recent findings of the impacts of addictive substances of abuse on the brain and the actions of their abuse; new chemical compounds, including immunotherapies; and new forces of available prescriptions are giving many chances for the finding and growth of novel prescriptions to treat addictive syndromes. Developments in the understanding of the genetic and epigenetic basis of drug abuse and the pharmacogenetics of the safety and/or effectiveness of the prescriptions are giving chances for more distinct pharmacotherapy methods.
Although multiple prescriptions have been evaluated for treating addictions, only a handful have displayed acceptable safety and effectiveness and are approved by the US Food and Drug Administration. This paper evaluates the current prescriptions that are medically sound and have displayed promising conclusions for treating:
The growth of prescriptions to cure addiction is quite an active area of study. The stage of growth and degree of success of novel prescriptions vary relying on the type of addictive syndrome. Pharmacotherapies for opioid addiction are at the ready, but new mixtures of naltrexone and buprenorphine and new pharmacologic methods beyond the opioid receptor soon may be giving new alternatives for their treatment. Prescriptions for cocaine abuse have been studied massively in the past 20 years, but none have been given the thumbs up by the FDA for this indication. Prescriptions such as:
All might give an acceptable sign of effectiveness for curing cocaine abuse alone or in tandem with other psychiatric syndromes. The growth of pharmacotherapies for addictive disorders and cannabis abuse is in its larval stages, but current findings of their method of action and growth of abuse are giving fresh chances to find safe, efficient prescriptions for their treatment.
For addictive disorders, medications such as bupropion, modafinil, rivastigmine, and lobeline may be right on for curing addiction withdrawal or reliance. Finally, given the great developments in knowing the endocannabinoid network and the impacts of marijuana on the central nervous system in recent years, there has been growing interest in developing pharmacotherapies for marijuana abuse and/or withdrawal and assessing cannabinoids for the treatment of other abuse disorders.
The cannabinoid agonists and antagonists and prescriptions with actions on different neurotransmitter networks are being developed. With the current developments in the understanding of the neurobiology of abuse and the growth of new pharmacotherapies for these syndromes, it is hoped that more prescription options will be available for the treatment of addictive syndromes in the not-too-distant future.